FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2520834639> ?p ?o ?g. }

• W2520834639 endingPage "432" @default.
• W2520834639 startingPage "432" @default.
• W2520834639 abstract "Abstract Abstract 432 Elotuzumab is a humanized monoclonal IgG1 antibody directed against CS1, a cell surface glycoprotein, which is highly and uniformly expressed in multiple myeloma (MM). Elotuzumab induces significant antibody-dependant cytotoxicity (ADCC) against primary myeloma cells in the presence of either autologous or allogeneic peripheral lymphocytes (PBMC), which is significantly enhanced when PBMC effector cells were pretreated with lenalidomide (Tai et al., Blood 112:1329, 2008). The primary objective of the phase 1 portion of the study is to evaluate the maximum tolerated dose (MTD) of elotuzumab in combination with lenalidomide and low dose dexamethasone in patients with relapsed MM. The study is also evaluating safety, pharmacokinetics (PK) and clinical response. Lenalidomide (25 mg PO) is given on Days 1-21 of a 28-day cycle. Elotuzumab in three escalating dose cohorts (5, 10 and 20 mg/kg) is administered by IV infusion on Days 1, 8, 15 and 22 of the 28-day cycle in the first two cycles and then on Days 1 and 15 of each subsequent cycle. Dexamethasone is given weekly at 40 mg PO. Initially, patients received 6 cycles of treatment unless withdrawn earlier due to disease progression or unacceptable. toxicity. The protocol was amended to allow for patients in the 10 and 20 mg/kg cohorts to receive treatment for up to 12 months following enrollment of the last patient. Key entry criteria: age ≥ 18 years; MM with at least one relapse; measurable disease M-protein component in serum and/or in urine; and prior lenalidomide treatment, if any, more than 6 weeks of first dose. To date, 24 patients with a median age of 60 years have been enrolled in the study and 23 patients have received study drug. The median time from initial diagnosis of MM was 5 years and patients had received a median of 3 prior MM treatments. Patients had been previously treated with thalidomide (58%), bortezomib (67%) or lenalidomide (21%) and 42% were refractory to their most recent MM therapy. Patients have been treated in the 3 cohorts; 3 patients each in the first two cohorts (5 and 10 mg/kg elotuzumab) and 17 patients (7 in dose-escalation phase and 10 in the expansion phase) in the third cohort (20 mg/kg). No dose limiting toxicities were identified during the dose-escalation phase of the study and no MTD was established. One patient discontinued in the first cycle due to grade 4 allergic reaction resulting from elotuzumab infusion in the expansion phase of the study. Additional SAEs (1 of each) included grade 2 atrial fibrillation (related to lenalidomide/dexamethasone) and unrelated grade 4 ruptured diverticulum, grade 3 neutropenic fever and grade 3 diarrhea.. Other common grade 3 or 4 AEs included neutropenia (25%) and thrombocytopenia (25%), which were managed by dose withholding or dose reduction of lenalidomide. Approximately 25% of patients experienced grade 1 or 2 chills and/or pyrexia associated with elotuzumab infusion. The best clinical response (IMWG criteria) in the 13 patients who have received at least two cycles of treatment is shown in the table below. Preliminary PK analysis of elotuzumab suggests a serum half-life of 10-11 days at 10 and 20 mg/kg. Elotuzumab at all three doses resulted in near complete saturation of CS1 sites on plasma cells and NK cells in bone marrow and NK cells in the peripheral compartment. In conclusion, the combination of elotuzumab with lenalidomide and low-dose dexamethasone has a manageable adverse event profile and compared to historical data for lenalidomide and high-dose dexamethasone, the preliminary efficacy data (≥ PR of 92%) are very encouraging. Additional safety, efficacy and PK/PD data will be presented at the meeting. Disclosures: Lonial: Celgene: Consultancy; Millennium: Consultancy, Research Funding; BMS: Consultancy; Novartis: Consultancy; Gloucester: Research Funding. Off Label Use: Lenalidomide/dexamethasone in combination with elotuzumab in patients with relapsed/refractory multiple myeloma. Vij:Celgene: Research Funding, Speakers Bureau. Harousseau:Celgene France: Advisory Board; Janssen Cilag France: Advisory Board; Celgene: Honoraria; Janssen Cilag: Honoraria; Novartis: Honoraria; Amgen: Honoraria. Facon:Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Kaufman:Celgene: Consultancy, Research Funding; Millennium: Consultancy; Genzyme: Consultancy; Merck: Research Funding. Mazumder:Celgene: Speakers Bureau; Millennium: Speakers Bureau. Leleu:Celgene: Research Funding, Speakers Bureau. Fry:Facet Biotech: Employment. Singhal:Facet Biotech: Employment. Jagannath:Millennium: Advisory Board; Merck: Advisory Board." @default.
• W2520834639 created "2016-09-23" @default.
• W2520834639 creator A5002061358 @default.
• W2520834639 creator A5013047847 @default.
• W2520834639 creator A5014513613 @default.
• W2520834639 creator A5023276777 @default.
• W2520834639 creator A5026151069 @default.
• W2520834639 creator A5028046297 @default.
• W2520834639 creator A5048560248 @default.
• W2520834639 creator A5069449708 @default.
• W2520834639 creator A5071589084 @default.
• W2520834639 creator A5071792303 @default.
• W2520834639 creator A5077897003 @default.
• W2520834639 date "2009-11-20" @default.
• W2520834639 modified "2023-10-02" @default.
• W2520834639 title "Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results." @default.
• W2520834639 doi "https://doi.org/10.1182/blood.v114.22.432.432" @default.
• W2520834639 hasPublicationYear "2009" @default.
• W2520834639 type Work @default.
• W2520834639 sameAs 2520834639 @default.
• W2520834639 citedByCount "7" @default.
• W2520834639 countsByYear W25208346392012 @default.
• W2520834639 countsByYear W25208346392015 @default.
• W2520834639 countsByYear W25208346392020 @default.
• W2520834639 crossrefType "journal-article" @default.
• W2520834639 hasAuthorship W2520834639A5002061358 @default.
• W2520834639 hasAuthorship W2520834639A5013047847 @default.
• W2520834639 hasAuthorship W2520834639A5014513613 @default.
• W2520834639 hasAuthorship W2520834639A5023276777 @default.
• W2520834639 hasAuthorship W2520834639A5026151069 @default.
• W2520834639 hasAuthorship W2520834639A5028046297 @default.
• W2520834639 hasAuthorship W2520834639A5048560248 @default.
• W2520834639 hasAuthorship W2520834639A5069449708 @default.
• W2520834639 hasAuthorship W2520834639A5071589084 @default.
• W2520834639 hasAuthorship W2520834639A5071792303 @default.
• W2520834639 hasAuthorship W2520834639A5077897003 @default.
• W2520834639 hasConcept C112705442 @default.
• W2520834639 hasConcept C126322002 @default.
• W2520834639 hasConcept C143998085 @default.
• W2520834639 hasConcept C2776063141 @default.
• W2520834639 hasConcept C2776364478 @default.
• W2520834639 hasConcept C2776694085 @default.
• W2520834639 hasConcept C2778822529 @default.
• W2520834639 hasConcept C2780401358 @default.
• W2520834639 hasConcept C71924100 @default.
• W2520834639 hasConcept C90924648 @default.
• W2520834639 hasConcept C98274493 @default.
• W2520834639 hasConceptScore W2520834639C112705442 @default.
• W2520834639 hasConceptScore W2520834639C126322002 @default.
• W2520834639 hasConceptScore W2520834639C143998085 @default.
• W2520834639 hasConceptScore W2520834639C2776063141 @default.
• W2520834639 hasConceptScore W2520834639C2776364478 @default.
• W2520834639 hasConceptScore W2520834639C2776694085 @default.
• W2520834639 hasConceptScore W2520834639C2778822529 @default.
• W2520834639 hasConceptScore W2520834639C2780401358 @default.
• W2520834639 hasConceptScore W2520834639C71924100 @default.
• W2520834639 hasConceptScore W2520834639C90924648 @default.
• W2520834639 hasConceptScore W2520834639C98274493 @default.
• W2520834639 hasIssue "22" @default.
• W2520834639 hasLocation W25208346391 @default.
• W2520834639 hasOpenAccess W2520834639 @default.
• W2520834639 hasPrimaryLocation W25208346391 @default.
• W2520834639 hasRelatedWork W1968654086 @default.
• W2520834639 hasRelatedWork W1996748901 @default.
• W2520834639 hasRelatedWork W2128903704 @default.
• W2520834639 hasRelatedWork W2318990278 @default.
• W2520834639 hasRelatedWork W2345460629 @default.
• W2520834639 hasRelatedWork W2466939543 @default.
• W2520834639 hasRelatedWork W2564869059 @default.
• W2520834639 hasRelatedWork W2765526403 @default.
• W2520834639 hasRelatedWork W3007230085 @default.
• W2520834639 hasRelatedWork W3121407702 @default.
• W2520834639 hasVolume "114" @default.
• W2520834639 isParatext "false" @default.
• W2520834639 isRetracted "false" @default.
• W2520834639 magId "2520834639" @default.
• W2520834639 workType "article" @default.